![](https://investorshub.advfn.com/uicon/825665.png?cb=1657717173)
Friday, November 04, 2022 4:26:54 AM
The market sentiments now is filled with uncertainty and fear, seeing large drops of more than 50% in major large market capital stock prices. (especially in the tech sector). The negative contributions are non other than the rise in inflationary and Consumer Price Index (CPI) numbers which have recorded to beat analysis estimates, sending market lower to the bearish pits.
Volatile periods calls for a reshuffling of portfolio in many investors and traders where they may opt for defensive sector equities ie. REITs, F&B, Utilities or Healthcare which has shown resilience against market turbulent.
Regencell Bioscience Limited’s (NASDAQ:RGC) a bioscience and healthcare company which focuses heavily on R&D and commercialization of Traditional Chinese Medicine (”TCM”) treatment specifically Attention Deficit Hyperactivity Disorder (”ADHD”) and Autism Spectrum Disorders (”ASD”), and infectious diseases affecting people’s immune system such as COVID.
The stock price has seen over 300% growth since IPO and had seen fallen victim to short sellers and hedge funds which took the shares down. Recently the share price has rose over 30% . The stock price has shown major resilience towards market volatility and could be contributed to its strong backing of the company CEO (Mr Au) whom has bought over $5 Million Dollars worth of company share in recent period and not sold any since its IPO inception.
The CEO has also demonstrated commitment towards the company by just being paid $1 Dollars annually and will receive no bonuses until the company’s market capital is reached $1 Billion Dollars. Early investors within the company (ie. directors and employees) have agreed to a stock option lockup period of 6 months after the stock option becomes vested. (lock up till 16th January 2023).
Having the full support and confidence of the company CEO and its employees, we hope to see further upside and positive news on the company, especially on treatments of ADHD, ASD & Covid19 with the company’s TCM method.
[https://www.morningstar.com/news/business-wire/20220516005531/regencell-bioscience-holdings-limited-announces-over-5-million-ordinary-share-purchases-by-ceo]
Recent RGC News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/20/2024 01:13:05 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/02/2024 11:04:03 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/15/2023 11:09:52 AM
- Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/27/2023 08:15:39 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM